Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients in the eXpeRience registry (safety population)

From: Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting

Variable

Patients on OCS at baseline

(n = 263)

Overall population

(n = 925)

Mean age, years (SD)

46.0 (13.3)

45.0 (15.0)

Female, n (%)

169 (64.3)

600 (64.9)

Race, n (%)

 

   Caucasian

246 (93.5)

855 (92.4)

   Others

17 (6.5)

70 (7.6)

Mean duration of allergic asthma, years (SD)

20.3 (13.6) [n = 261]

19.4 (13.6)

Positive skin-prick test/RAST for perennial aeroallergens, n (%)

232 (88.2)

816 (88.2)

History of seasonal allergy, n (%)

177 (67.3)

587 (63.5)

Smoking history, n (%)

 

   Never smoked

202 (76.8)

719 (77.7)

   Ex-smoker

52 (19.8)

173 (18.7)

   Current smoker

9 (3.4)

30 (3.2)

Asthma clinical symptoms, n (%)

  

   Daytime asthma symptoms

245 (93.2)

838 (90.6)

   Limitations of activities

239 (90.9)

795 (85.9)

   Nocturnal symptoms/awakenings

218 (82.9)

737 (79.7)

Asthma control (investigator assessment), n (%)

  

   Controlled

3 (1.1)

13 (1.4)

   Partly controlled

42 (16.0)

215 (23.2)

   Uncontrolled

218 (82.9)

693 (74.9)

  1. Data missing for one patient; Data missing for three patients.
  2. RAST, radioallergosorbent test; SD, standard deviation.